Insider Selling: Jeffrey M. Leiden Unloads 35,944 Shares of Vertex Pharmaceuticals Stock (VRTX)
Vertex Pharmaceuticals (NASDAQ:VRTX) CEO Jeffrey M. Leiden unloaded 35,944 shares of the company’s stock on the open market in a transaction dated Friday, February 7th. The stock was sold at an average price of $80.00, for a total value of $2,875,520.00. Following the transaction, the chief executive officer now directly owns 211,481 shares of the company’s stock, valued at approximately $16,918,480. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Separately, analysts at UBS AG upgraded shares of Vertex Pharmaceuticals from a “neutral” rating to a “buy” rating in a research note on Monday, January 6th. They now have a $99.00 price target on the stock, up previously from $84.00. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have issued a buy rating to the stock. Vertex Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $93.29.
Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) traded up 3.42% during mid-day trading on Tuesday, hitting $84.98. The stock had a trading volume of 1,439,008 shares. Vertex Pharmaceuticals has a one year low of $43.69 and a one year high of $89.96. The stock’s 50-day moving average is $78.0 and its 200-day moving average is $74.19. The company’s market cap is $19.867 billion.
Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Wednesday, January 29th. The company reported ($0.56) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.49) by $0.07. The company had revenue of $351.20 million for the quarter, compared to the consensus estimate of $221.08 million. During the same quarter in the prior year, the company posted ($0.35) earnings per share. The company’s quarterly revenue was up 5.1% on a year-over-year basis. On average, analysts predict that Vertex Pharmaceuticals will post $-2.33 earnings per share for the current fiscal year.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.